Back to Stakeholders

Clinical Research & Pipeline Products Company-Led Drug Development & Commercialization

COMPASS Pathways

United Kingdom

14 Trials

COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.

Quick Facts

Type: Public Biotech
HQ: United Kingdom
Website: Visit

Sponsored Trials

8

Active not recruitingIII

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD (COMP 006)

Start Date: February 1, 2023
Compounds: Psilocybin

Active not recruitingII

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Major Depressive Disorder With One Prior Treatment Failure

Start Date: January 30, 2023
Compounds: Psilocybin

Active not recruitingIII

Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD (COMP005)

Start Date: November 30, 2022
Compounds: Psilocybin, Placebo

Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

Start Date: August 1, 2022
Compounds: Psilocybin

The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Start Date: April 11, 2022
Compounds: Psilocybin

The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression

Start Date: September 15, 2020
Compounds: Psilocybin

Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)

Start Date: July 20, 2020

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

Start Date: January 1, 2019
Compounds: Psilocybin

Collaborated Trials

6

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

Start Date: June 1, 2022
Compounds: Psilocybin

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

Start Date: January 24, 2022
Compounds: Psilocybin

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

Start Date: May 1, 2021
Compounds: Psilocybin

Active not recruitingII

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

Start Date: March 1, 2021
Compounds: Psilocybin

Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

Start Date: February 26, 2021
Compounds: Psilocybin

Unknown statusII

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression

Start Date: January 3, 2021
Compounds: Psilocybin